Mohammad Thawabi, MD
Interventional Cardiology · Indianapolis, INNPI 1356730881
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $8,411 of the $10,981 with a category attached, or 76.6%. It is spread thinly across 28 manufacturers, the largest accounting for just 20.3% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2019 at $4,323 and has fallen 90.6% since, to $405 in 2025.
Across 288 payments — averaging $38.13 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Medtronic$2K
- Terumo Medical Corporation$2K
- Abbott$1K
- Cardiovascular Systems Inc.$1K
- Novartis$959
- Abiomed$591
- plus $4K from 22 others
Across 12 payments — averaging $10,383 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Medtronic$125K
What the payments were for
- Travel & lodging$2,57023%
- Food & beverage$8,41177%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Medtronic(2 entities) | 34 | $2,232 |
| Terumo Medical Corporation | 14 | $1,524 |
| Abbott | 26 | $1,072 |
| Cardiovascular Systems Inc. | 26 | $1,044 |
| Novartis | 53 | $959 |
| Abiomed | 11 | $591 |
| Amgen | 17 | $499 |
| AstraZeneca | 20 | $489 |
| Boston Scientific | 8 | $457 |
| Bard Peripheral Vascular, Inc. | 5 | $368 |
| Boehringer Ingelheim | 9 | $307 |
| Johnson & Johnson | 16 | $275 |
| Endotronix, Inc. | 2 | $190 |
| Pfizer | 12 | $190 |
| Edwards Lifesciences | 5 | $135 |
| E.r. Squibb & Sons, L.L.C. | 8 | $120 |
| Regeneron Healthcare Solutions, Inc. | 5 | $114 |
| Esperion Therapeutics, Inc. | 5 | $93 |
| Livanova USA, Inc. | 1 | $91 |
| Merck | 2 | $49 |
| Cvrx, Inc. | 1 | $33 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 2 | $33 |
| Shockwave Medical, Inc | 1 | $32 |
| Otsuka America Pharmaceutical, Inc. | 1 | $21 |
| Sanofi-aventis U.S. LLC | 1 | $18 |
| Cardiva Medical, Inc. | 1 | $18 |
| Chiesi USA, Inc. | 1 | $16 |
| Bayer | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- HawkOne$1,486
- TR Band$842
- Impella$380
- Optis Coronary Imaging System$278
- R2P MISAGO$236
- Diamondback Peripheral$235
- Diamondback Coronary$235
- Repatha$232
- Peripheral Orbital Atherectomy System$228
- Coronary Orbital Atherectomy System$228
- WATCHMAN Access System$146
- GlideWire$134
- ENTRESTO$125
- FARXIGA$125
- JARDIANCE$121
- IN.PACT Admiral$120
- HeartMate 3 Left Ventricular Assist Device$113
- OPTIS$108
How this compares
$10,981 in reported general payments places this provider in the 60th percentile of 170 interventional cardiology providers in Indiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 133 | $124,391 |
| JardianceEmpagliflozin | 62 | $65,813 |
| EntrestoSacubitril/Valsartan | 54 | $54,153 |
| FarxigaDapagliflozin Propanediol | 36 | $34,344 |
| Repatha SureclickEvolocumab | 45 | $31,545 |
| XareltoRivaroxaban | 43 | $26,834 |
| MultaqDronedarone Hcl | 11 | $12,618 |
| LivaloPitavastatin Calcium | 16 | $7,666 |
| Praluent PenAlirocumab | 11 | $5,213 |
| Valsartan | 95 | $3,529 |
| Ezetimibe | 91 | $2,975 |
| Atorvastatin Calcium | 231 | $2,915 |
| Metoprolol Succinate | 155 | $2,024 |
| Rosuvastatin Calcium | 99 | $1,550 |
| ClopidogrelClopidogrel Bisulfate | 156 | $1,500 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $190 | $124,391133 claims |
| Boehringer IngelheimJardiance | $307 | $65,81362 claims |
| NovartisEntresto | $959 | $54,15354 claims |
| AstraZenecaFarxiga | $489 | $34,34436 claims |
| Johnson & JohnsonXarelto | $275 | $26,83443 claims |
| Sanofi-aventis U.S. LLCMultaq | $18 | $12,61811 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 170 interventional cardiology providers in Indiana.
Other interventional cardiology in Indianapolis
- James HermillerIndianapolis$307K
- Woodrow CoreyIndianapolis$262K
- Michael BallIndianapolis$76K
- Anjan SinhaIndianapolis$54K
- Nitesh GadeelaIndianapolis$48K
- George RevtyakIndianapolis$45K
- Scott SharpIndianapolis$41K
- Amrish MalhiIndianapolis$37K
- Jeffrey BreallIndianapolis$21K
- Sandeep DubeIndianapolis$21K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.